Site searchCompany Overview & History
Company Overview
| Company Name | BrightPath Biotherapeutics Co., Ltd. |
|---|---|
| Location |
Corporate Headquarters: Kojimachi Central Building 7F, 2-2-4 Kojimachi, Chiyoda-ku, Tokyo MAPKawasaki Research Laboratories: |
| Established | May 8, 2003 |
| Capital Stock | 6,700 million yen（as of March 31, 2022） |
| Number of Employees | 38 people（as of March 31, 2022） |
History
| May 2003 | Established at Kurume, Fukuoka Prefecture |
|---|---|
| January 2006 | Started a phase I clinical trial of ITK-1 for castration-resistant prostate cancer |
| November 2011 | Reached an out-license agreement on ITK-1 with FUJIFILM Corporation |
| June 2013 | Started a phase III clinical trial of ITK-1 for castration-resistant prostate cancer |
| June 2015 | Interim analysis of the phase III study trial of ITK-1 in CRPC completed & the study continued as planned |
| October 2015 | Started a phase I clinical trial of GRN-1201 for melanoma in the US Listed on the Tokyo Stock Exchange (code:4594) |
| August 2016 | Opened Kawasaki Research Laboratory at Kawasaki, Kanagawa prefecture |
| January 2017 | Started a phase II clinical trial of GRN-1201 in combination with an immune checkpoint antibody in patients with non-small cell lung cancer in the US |
| July 2017 | Changed company name from GreenPeptide to BrightPath Biotherapeutics |
| April 2018 | Joined iPS-NKT development project promoted by RIKEN |
| May 2018 | Opened the keys-code of the phase III double-blind placebo-controlled study for ITK-1 |
| May 2019 | Terminated development of ITK-1 |
| June 2020 | Started Phase I clinical trial of iPS-NKT for head and neck cancer |
| May 2022 | Started Phase I clinical trial of HER2-targeted CAR-T cell therapy BP2301 |
| May 2022 | Announced the early termination of a phase II clinical trial of GRN-1201 in combination with an immune checkpoint antibody in patients with non-small cell lung cancer in the US |